Celgene Snags Cancer Treatment Co. Avila For $350M

Law360, New York (January 26, 2012, 5:41 PM EST) -- Celgene Corp. has paid $350 million in cash to acquire Avila Therapeutics Inc., a biotechnology company whose potential cancer treatment has shown promise in clinical studies, Celgene said Thursday.

The acquisition of Bedford, Mass.-based Avila and its AVL-292 treatment allows Celgene to further expand its research of novel therapies for hematology, oncology and autoimmune diseases, Celgene said. Depending on the development and regulatory approval of AVL-292, Celgene may pay up to $195 million in additional milestone payments under the deal, Celgene said.

Celgene viewed Avila’s approach...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.